Intrathecal substance P-saporin in the dog: efficacy in bone cancer pain.
Intrathecal substance P-saporin in the dog: efficacy in bone cancer pain.
复制标题
DOI：
10.1097/aln.0b013e3182a95188
复制
发表时间：
2013-11
期刊：
影响因子：
8.8
通讯作者：
Agnello K
中科院分区：
文献类型：
--
作者：
Brown DC;Agnello K
Substance-p saporin (SP-SAP), a chemical conjugate of substance-p and a recombinant version of the ribosome-inactivating protein, saporin, when administered intrathecally, acts as a targeted neurotoxin producing selective destruction of superficial neurokinin 1 receptor bearing cells in the spinal dorsal horn. The goal of this project was to provide proof of concept data, that a single intrathecal injection of SP-SAP could safely provide effective pain relief in spontaneous bone cancer pain in companion (pet) dogs. In a single blind, controlled study, 70 companion dogs with bone cancer pain were randomized to standard of care analgesic therapy alone (control, n=35) or intrathecal SP-SAP (20-60μg) in addition to standard of care analgesic therapy (n=35). Activity, pain scores, and videography data was collected at baseline, 2 weeks post randomization, and then monthly until death. While the efficacy results at the 2-week post randomization point were equivocal, the outcomes evaluated beyond two weeks revealed a positive effect of SP-SAP on chronic pain management. Significantly more dogs in the control group (74%) required unblinding and adjustment in analgesic protocol or euthanasia within 6 weeks of randomization, than dogs that were treated with SP-SAP (24%; p<0.001); and overall, dogs in the control group required unblinding significantly sooner than dogs that had been treated with SP-SAP (p<0.01). Intrathecal SP-SAP administration in dogs with bone cancer produces a time dependent anti-nociceptive effect with no evidence of development of deafferentation pain syndrome that can be seen with neurolytic therapies.
